Celsee Diagnostics Adds Industry Veteran John L. “Kip” Miller to its Board
Celsee Diagnostics, an innovator of cutting-edge rare and single cell detection products, announced the appointment of John L. “Kip” Miller to its Board of Directors.
Mr. Miller is an accomplished executive and entrepreneur with a proven track record of developing and growing global life science businesses, most notably at Life Technologies (now ThermoFisher Scientific) and BD Biosciences. Mr. Miller has built a strong background in executive leadership, M&A, and commercial operations and has developed extensive experience in the segments of research life sciences, genomics and diagnostics.
Until 2011, he served as President of the Genetic Systems at Life Technologies, an approximately $1B division of a market-leading provider of DNA sequencing systems developed for academic research, applied market segments for human identification, and clinical diagnostics.
Prior to the formation of Life Technologies, Kip served as Senior Vice President of Invitrogen (2005-2008) where he led the ~$650M Biodiscovery division, a leading developer of life science tools and enabling technologies for biomedical research, pharmaceutical drug discovery services, and transplantation diagnostics. The division became the market-leading developer and provider of tools and enabling technologies for biomedical research involved in molecular biology, proteomics and cellular analysis.
Before joining Invitrogen Corporation, Mr. Miller served as Vice President and General Manager at BD Biosciences (San Diego/ San Jose, CA) from November 1992 to November 2005. During this period, Mr. Miller was responsible for the development of BD Biosciences research flow cytometry instrumentation, research immunology reagents and for the company’s Commercial Operations across the Americas.
Mr. Miller is actively involved with several life sciences start-up companies. He is co-founder of San Diego based Tonbo Biosciences, and serves as a board member for multiple companies involved in genomic research and diagnostics.
“We are pleased to expand the capabilities of our board with an executive who possesses such an exceptional track of growing life science businesses,” said Kalyan Handique, President and CEO of Celsee Diagnostics. “With Celsee on its early commercialization path, our team will greatly benefit from Kip’s commercial and operational expertise.”
“I am excited to join the board of Celsee and am looking forward to the opportunity to work with their experienced and talented team,” said Mr. Miller. “The field of single cell genomics is one of the fasted growing segments in life sciences and Celsee has developed a suite of platform technologies that promise to simplify and improve upon existing single cell workflows that promise to accelerate discovery and disease diagnostics.”
About Celsee Diagnostics
Celsee Diagnostics, a privately-held Michigan-based company, develops, manufactures and sells innovative, integrated systems for rare and single cell analysis for Oncology/Immuno-Oncology research and clinical applications. The label-free Celsee™ PREP platforms perform all the required processing steps to isolate and execute downstream single-cell analysis including immunochemistry, DNA FISH and mRNA FISH, while the Celsee ANALYZER scans and analyzes the prepared slide automatically. The Celsee SingleCell™ system integrates isolation, staining and retrieval providing an unprecedented yield of viable cells for culture, PCR or NGS, at a cost savings of 10-20x that of competitive systems.